Company Strengthens Industry Leadership Through Educating Medical Community on Therapeutic Uses of Cannabis for Treating Neurodegenerative Diseases
San Diego, CA – Oct. 4, 2016 – Medical Marijuana, Inc. (OTC: MJNA) today announced that its subsidiary HempMeds® Mexico will hold the first-ever symposium dedicated to providing the medical community with information about the medical value of cannabidiol (CBD) derivatives in the treatment of neurodegenerative diseases.
The First National Symposium on Medical Cannabis, which will take place on Oct. 8 in Mexico City, is part of the Company’s program to educate health professionals on the therapeutic uses of cannabis and will feature renowned experts like Dr. Saul Garza Morales, pediatric neurologist and researcher in Mexico, and Raul Elizalde, an important activist working for access to medical products derived from cannabis. Both will share their experience in treating pediatric patients, as well as on human rights and gaining access to medical cannabis for improving health and quality of life.
HempMeds® Mexico’s zero-Tetrahidrocannabidiol (THC) Real Scientific Hemp Oil-X™ (RSHO-X™) was the first-ever cannabis product to receive approval from the federal government of Mexico, COFEPRIS, for importation. RSHO-X™ is also the first cannabis-based product to qualify as safe for World Anti-Doping standards and therefore could be used without concern by Olympic athletes or those who are regularly drug-tested for THC or synthetic THC cannabinoids.
“We are proud to be a company of firsts, including being the first publicly traded cannabis company in the United States,” said Chief Executive Officer of Medical Marijuana, Inc. Dr. Stuart Titus. “Our products have been the first to be approved by regulatory health agencies in Mexico and elsewhere in Latin America, and we are now proud to be the first Company to establish rapprochement programs for the medical community. We are dedicated to actively educating health professionals on the plethora of benefits that medical cannabis provides to treat several types of indications.”
The event will also serve as a forum to discuss current research on cannabinoids such as CBD, including research on using cannabinoids as anti-inflammatory, anticonvulsants, antioxidant and even antipsychotic agents. In addition, the event will be a place for doctors and researchers to share international experience on the use of derivatives of cannabis in the treatment of neurodegenerative diseases.
During the event, the value of hemp derivatives will be reviewed, and how they offer a potential alternative to regulators since these hemp derivatives contain non-psychoactive cannabinoids. Although Mexico’s COFEPRIS has maintained a strict zero-THC policy, the Company will educate doctors on the value of all cannabinoids, as world standards move towards a 0.3% to 1% threshold for distinguishing hemp vs. marijuana. The Entourage Effect, a critical part of the natural botanical hemp plant and its potential therapeutic benefit, will also be explored and why a full spectrum cannabinoid profile is preferable for therapeutic evaluation.
“One of our objectives is to share with health professionals the results of international clinical studies that focus on the neuroprotective properties of cannabinoids, as well as several clinical applications,” said Dion Markgraaf, President of HempMeds Mexico. “Brazil, for example, is a country where cannabinoids have not only been approved, but also are 100% subsidied by the Brazillian government, as they are fully informed about their value for the treatment of various diseases.”
About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at: http://www.hempmeds.mx.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer
Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
Investor Relations Contact:
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: [email protected]